We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Major Advancement Detects Cystic Fibrosis Lung Infections

By LabMedica International staff writers
Posted on 09 Aug 2015
A novel diagnostic approach has been developed that offers an unprecedented rapid and accurate diagnosis of lung infections in patients with cystic fibrosis, a disease affecting around 9,000 people in the UK. More...


Respiratory infection in cystic fibrosis (CF) is polymicrobial, but standard sputum microbiology does not account for the lung microbiome or detect changes in microbial diversity associated with disease.

Scientists at the University Hospital of South Manchester (UK) and their colleagues collected 200 sputum specimens from 93 CF patients. In all cases, CF had been diagnosed prior to study entry on the basis of clinical, biochemical, and genetic results in line with standard clinical practice. At each visit, patients provided paired sputum samples for conventional culture and culture-independent analysis and ribosomal intergenic spacer analysis (RISA) and 16S ribosomal ribonucleic acid (rRNA) gene pyrosequencing.

RISA polymerase chain reaction (PCR) was performed and the 2 μL of amplified DNA amplicons were separated by the 2100 Bioanalyzer microfluidics (Agilent Technologies; Santa Clara, CA, USA), and their profiles were analyzed using Gelcompar II (Applied Maths; Sint-Martens Latem, Belgium). A subset of samples from 60 patients representative of the diversity observed by RISA profile cluster analysis were selected for 16S rRNA gene pyrosequencing analysis performed by Research and Testing Laboratory Inc. (Lubbock, TX, USA).

Compared to the microbiology data, RISA profiles clustered into two groups: the emerging non-fermenting Gram-negative organisms (eNFGN) and Pseudomonas groups. Patients who were culture positive for Burkholderia, Achromobacter, Stenotrophomonas, and Ralstonia clustered within the eNFGN group. Pseudomonas group RISA profiles were associated with Pseudomonas aeruginosa culture-positive patients.

The authors concluded that nucleic acids isolated from CF sputum can serve as a single template for both molecular virology and bacteriology, with a RISA PCR rapidly detecting the presence of dominant eNFGN pathogens or P. aeruginosa missed by culture as was observed in 11% of cases. They showed how this straightforward CF microbiota profiling scheme may be adopted by clinical laboratories.

Eshwar Mahenthiralingam, PhD, a senior author of the study, said, “By taking advantage of existing virology sample processing methods, and applying simple bacterial genetic tests, we can accurately diagnose infections with very problematic antibiotic-resistant bacteria. Better diagnosis of these infections will improve treatment, quality of life and survival for people with cystic fibrosis.” The study was published in the July 2015 issue of the Journal of Clinical Microbiology.

Related Links:
University Hospital of South Manchester
Agilent Technologies 
Applied Maths 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.